Fisetin Attenuates Uterine Leiomyoma in Rats: Potential Crosstalk Between HMGB1, SphK1/S1P, and TGF‐β Signaling
Nashwa Maghraby, Esraa Khalaf, Marwa T. Hussien, Ahmed M. A. Sobh, Nagla T. Elmelegy · 2026
Read Fisetin Attenuates Uterine Leiomyoma in Rats: Potential Crosstalk Between HMGB1, SphK1/S1P, and TGF‐β Signaling by Nashwa Maghraby, Esraa Khalaf, Marwa T. Hussien, Ahmed M. A. Sobh, Nagla T. Elmelegy (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13528568.txt.
Description
Maghraby and four co-authors test the plant compound fisetin in rats with uterine leiomyoma, in a 2026 paper. These benign tumors are common and carry a large medical and economic load. Treatments that save the uterus and fertility are still lacking.
Tumors were induced in female rats, and some were then given fisetin. Blood tests, gene measures, and tissue checks were compared across groups. Fisetin lowered raised sex hormones and cut signals tied to inflammation and fibrosis. Tissue samples showed less fibrotic change and better structure. The authors suggest fisetin acts across several linked pathways. They propose it as a candidate uterus-preserving treatment.
Catalog record
| CREATOR | Nashwa Maghraby, Esraa Khalaf, Marwa T. Hussien, Ahmed M. A. Sobh, Nagla T. Elmelegy |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |